Commercial Credit Report for BioMaxima SA

CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals. Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue. We also offer solutions that can help ease private company financial risk assessment. Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively.

A partial report preview for BioMaxima SA is shown below. Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database. To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

	BioMaxima SA
ul. Vetterow 5
Phone: +48 814408371p:+48 814408371	LUBLIN, 20-277 Poland	Ticker: BMXBMX

Business Summary

BioMaxima SA is a Poland-based company active in the laboratory diagnostics sector. It manufactures and distributes reagents and equipment for the laboratory diagnosis. It produces reagents for the in vitro diagnosis. The main product groups offered by BioMaxima include: diagnostic reagents and analyzers for clinical biochemistry; rapid tests and readers for detecting infectious diseases, cancer markers, cardiac markers and drugs of abuse; urine analysis systems; hematology analyzers and reagents; ion-selective analyzers and reagents; reagents and immunological analyzers of cardiac markers; glucometers; analyzers for gasometric tests and critical blood parameters tests. The Company supplies hospitals and laboratories in Poland, as well as in Lithuania, Latvia, Romania and France. On March 20, 2014, the Company merged with its wholly owned subsidiary Cebo Sp z o o.

Scores and Ratings

FRISK^® Score	Z'' Score	PAYCE^® Score	DBT Index	Moody's Rating	Fitch Rating	DBRS Rating
Yes	Yes	-	-	-	-	-

Financials, News and Filings

Latest Statement	Last Audit	News	SEC Filings	Bankruptcy Filings	Suit & Judgment Filings	Tax Lien Filings
6/30/2024	12/31/2023	Yes	-	-	-	-

Industries

SIC Code	Description
2835	In vitro and in vivo diagnostic substances
3826	Laboratory analytical instruments

Officers and Directors

Title	Name	Age	Title Date	Start Date
Chairman of the Supervisory Board	RafalJelonek
Chairman of the Management Board	LukaszUrban	47	1/17/2017	12/1/2016
Vice Chairman of the Supervisory Board	KrzysztofMikosz			12/1/2016
9 additional Officers and Directors records available in full report.

General Information

Number of Employees:	115	(As of 12/31/2023)
Outstanding Shares:	4,193,118	(As of 6/30/2024)
Stock Exchange:	WAR
Fax Number:	+48 817442915

SITE MAP | ABOUT US | DIRECTORY | STOCK QUOTE: CRMZ | SIGN IN